PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 23129

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition (PRESERVE-006)

Disease Types: Genitourinary Cancer Research

Available at:

Norfolk (Brock Cancer Center)

Treatment Types

Services

Support During Cancer

Cancers We Treat

Blood Cancers

Blood Disorders

Find a Provider Near You

Clinical Research & Trials

Listen to our podcast

USO 23129

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition (PRESERVE-006)